Sequence Identification of Wound Infection with Celadon Clinical Software

Award Information
Agency: Department of Defense
Branch: Defense Health Program
Contract: W81XWH-12-C-0062
Agency Tracking Number: O112-H16-3039
Amount: $149,967.00
Phase: Phase I
Program: SBIR
Awards Year: 2012
Solitcitation Year: 2011
Solitcitation Topic Code: OSD11-H16
Solitcitation Number: 2011.2
Small Business Information
Celadon Laboratories, Inc.
6525 Belcrest Rd, Suite 521, Hyattsville, MD, -
Duns: 788153166
Hubzone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Raymond Peterson, Ph.D.
 Chief Science Officer
 (301) 683-2118
 peterson@celadonlabs.com
Business Contact
 Lawrence Kessner
Title: Chief Executive Officer
Phone: (301) 683-2117
Email: lkessner@celadonlabs.com
Research Institution
 Stub
Abstract
Infection with Acinetobacter baumanni, especially drug-resistant strains, is a serious threat to U.S. military personnel and to the U.S. population. Identification of wound pathogens and their drug susceptibility within minutes to hours, and administration of the appropriate drug, could significantly increase soldier and patient survival. Celadon and its consultants propose to: 1) Finalize 16S rRNA primer-directed amplification; 2) Select from the literature, or develop, primers to execute the amplification strategy; 3) Apply the strategy to 80 Acinetobacter baumanni strains at different concentration levels; 4) Compare PacBio RS to the most promising desk-top instrument; 5) Demonstrate prototype extension of Celadon Clinical software to sequence identification of wound pathogens. Microbiome consultants on this project are David A. Rasko, Ph.D. and Lynne M. Schriml, Ph.D., both of the Institute for Genome Sciences, University of Maryland School of Medicine. Nathan J. Edwards, Ph.D., of Georgetown Medical Center, Georgetown University, Washington, DC is consulting on selection of unique sequences. Michael J. Bosse, M.D., Principal Investigator of the DoD-funded BioBurden Study, will collect wound samples. The end result will be a substantial contribution to the development of a sequence-based test will provide the clinician with the information necessary to select the most appropriate antibiotic.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government